Latest News about Basal Cell Carcinoma
Recent news which mentions Basal Cell Carcinoma
Latest study demonstrates high efficacy in curing invasive non-melanoma skin cancer
October 25, 2023
From PRLog
Fully recruited EPIC-Skin international study for the treatment of Non-Melanoma Skin Cancer
July 11, 2023
Tickers
EPIC
From PRLog
GenesisCare and OncoBeta announce partnership to provide innovative treatment for non-melanoma skin cancer
May 17, 2023
From PRLog
Latest research shows Australians still not getting annual skin checks with a Health Professional
March 01, 2023
From PRLog
South African skin cancer patients undergo first treatments with OncoBeta's Rhenium-SCT as part of the EPIC-Skin study
December 22, 2022
From PRLog
'Spot Detective' – Check your spots this summer
November 22, 2022
From PRLog
London skin cancer patients undergo first treatments with OncoBeta's Rhenium-SCT as part of the EPIC-Skin study
September 27, 2022
From PRLog
German skin cancer patients join the EPIC-Skin study
July 28, 2022
From PRLog
Perth skin cancer patients undergo first treatments with OncoBeta's Rhenium-SCT as part of the EPIC-Skin study
June 15, 2022
From PRLog
From PRUnderground
Sydney skin cancer patients join the EPIC-Skin study as they undergo first treatments with OncoBeta's Rhenium-SCT
April 13, 2022
From PRLog
From PRLog
EPIC-Skin study welcomes world-first skin cancer patients treated with OncoBeta's Rhenium-SCT
March 10, 2022
From PRLog
First Patients Registered Into OncoBeta's International Registry For Non-Melanoma Skin Cancer Treatments
February 14, 2022
From PRLog
OncoBeta receives ethics approval for EPIC-Skin study to evaluate Rhenium-SCT in Australia
December 21, 2021
From PRLog
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.